Gilead Sciences Inc - GILD STOCK NEWS

Kite, a Gilead Company (Nasdaq: GILD), announced significant results from the Phase 3 ZUMA-7 study, demonstrating Yescarta's superiority in overall survival (OS) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) compared to historical standard treatment. This marks the first statistically significant OS improvement in nearly 30 years for initial treatment in this setting. The study showed a 2.5-fold increase in the two-year survival rate without cancer progression (40.5% vs. 16.3%) and a four-fold increase in median event-free survival (8.3 months vs. 2.0 months). These results underscore the potential of Yescarta as a leading treatment option for R/R LBCL.

Gilead Sciences announces Stacey Bledsoe as Head of Clinical Trial Diversity and Inclusion, aiming to enhance access to clinical trials for underrepresented racial and ethnic minorities.

Bledsoe's personal experience with her father's lung cancer drives her mission to combat inequities in cancer trial participation, where minorities only represent 10-15% of participants. Her strategy focuses on localized studies, culturally relatable providers, and community partnerships.

New initiatives include a partnership with Highland Hospital in Oakland and an educational campaign for Black History Month on triple-negative breast cancer trials.

Gilead Sciences aims to enhance clinical trials for HIV prevention through its PURPOSE studies, focusing on inclusivity among marginalized communities. The trials, PURPOSE 1 and PURPOSE 2, examine the effectiveness of investigational injections to lower HIV acquisition risk in women and diverse gender identities, respectively. Formation of Global Community Accountability Groups (G-CAGs) allows community leaders to influence trial design and participant recruitment. This innovative approach has already led to trial adjustments based on community feedback, promising a more representative data collection process.

Gilead Sciences has announced a donation of $1 million to support relief efforts for those affected by the recent earthquake in Türkiye and Syria. The Gilead Foundation will allocate the funds equally between the International Medical Corps and Direct Relief, both of which are long-standing partners of the company. This initiative underscores Gilead's commitment to social responsibility and aid in times of crisis. With a presence in over 35 countries and a headquarters in Foster City, California, Gilead is dedicated to developing innovative medicines for life-threatening conditions.

Gilead Sciences has reaffirmed its commitment to combating the HIV epidemic by supporting the AIDS Memorial Quilt, the largest living memorial project with over 50,000 panels and 110,000 names of those lost to HIV-related causes.

The Quilt serves as both a tribute and an educational tool for HIV prevention. Gilead is displaying blocks of the Quilt at its Foster City campus and is creating a dedicated panel for those lost to HIV within the company.

Gilead has been a long-time supporter of initiatives aiming to end the HIV epidemic and continues to innovate in biopharmaceuticals with a global presence in over 35 countries.

Gilead Sciences emphasizes the ongoing efforts to address the disproportionate impact of HIV on Black communities during Black HIV/AIDS Awareness Day. The company acknowledges significant progress in education and access to screening, prevention, and care but highlights the need for continued work in these areas. As a research-based biopharmaceutical organization, Gilead aims to transform care for life-threatening illnesses globally, maintaining operations in over 35 countries with its headquarters in Foster City, California. Gilead's commitment remains strong in combating HIV/AIDS and promoting health equity.

Gilead Sciences (NASDAQ: GILD) announces positive Phase 1b trial results for lenacapavir in combination with two broadly neutralizing antibodies, teropavimab and zinlirvimab, as an investigational long-acting HIV treatment. The trial involved 20 virologically suppressed participants, 90% of whom maintained viral suppression at 26 weeks. The treatment was well tolerated with no serious adverse events reported. Moving forward, Gilead plans to initiate a Phase 2 study to further assess the safety and efficacy of this combination therapy later this year. These findings may enhance treatment options and adherence for people living with HIV.

Kite, a Gilead Company (NASDAQ: GILD), has completed its acquisition of Tmunity Therapeutics, a clinical-stage biotech firm focused on next-generation CAR T-cell therapies. This strategic move enhances Kite's pipeline and capabilities, adding pre-clinical and clinical programs, including an advanced 'armored' CAR T technology platform. Along with this acquisition, Kite also establishes a research and licensing agreement with the University of Pennsylvania, ensuring continued collaboration with Tmunity's founders, who will provide consulting services. The deal aims to bolster Kite’s position in cell therapy for cancer treatment.

Gilead Sciences (NASDAQ: GILD) announced promising outcomes from three real-world studies on Veklury (remdesivir) regarding COVID-19 treatment. Initiating Veklury within two days of hospitalization showed a significant reduction in mortality rates across various patient groups, including immunocompromised individuals. The studies involving over 800 U.S. hospitals revealed a 19% to 26% lower risk of mortality at Day 28. Additionally, Veklury-treated patients experienced a 27% reduction in hospital readmissions within 30 days. The in vitro studies confirmed Veklury's effectiveness against recent Omicron subvariants, indicating its continuing relevance in evolving pandemic conditions.